1. Home
  2. MAS vs FEMY Comparison

MAS vs FEMY Comparison

Compare MAS & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Masco Corporation

MAS

Masco Corporation

HOLD

Current Price

$63.86

Market Cap

13.5B

Sector

Industrials

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.86

Market Cap

51.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAS
FEMY
Founded
1929
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.5B
51.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MAS
FEMY
Price
$63.86
$0.86
Analyst Decision
Buy
Strong Buy
Analyst Count
14
3
Target Price
$73.36
$6.83
AVG Volume (30 Days)
2.6M
1.9M
Earning Date
10-29-2025
11-14-2025
Dividend Yield
1.94%
N/A
EPS Growth
3.82
N/A
EPS
3.90
N/A
Revenue
$7,597,000,000.00
$2,061,502.00
Revenue This Year
N/A
$64.02
Revenue Next Year
$2.96
$147.19
P/E Ratio
$16.39
N/A
Revenue Growth
N/A
63.53
52 Week Low
$56.55
$0.31
52 Week High
$82.18
$1.80

Technical Indicators

Market Signals
Indicator
MAS
FEMY
Relative Strength Index (RSI) 51.02 51.24
Support Level $61.02 $0.79
Resistance Level $65.44 $0.91
Average True Range (ATR) 1.52 0.07
MACD 0.27 -0.02
Stochastic Oscillator 64.21 26.06

Price Performance

Historical Comparison
MAS
FEMY

About MAS Masco Corporation

Masco manufactures a variety of home improvement and building products. The company's $5 billion plumbing segment, led by the Delta and Hansgrohe brands, sells faucets, showerheads, and other related plumbing fixtures and components. The roughly $3 billion decorative architectural segment primarily sells paints and other coatings under the Behr and Kilz brands, but it also sells builder hardware products.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: